Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 6, 2009, Pages 440-447

  Nomura, Shosaku ^a   Shouzu, Akira ^b   Omoto, Seitarou ^c   Inami, Norihito ^c   Shimazu, Takayuki ^c   Satoh, Daisuke ^c   Kajiura, Takayuki ^c   Yamada, Kohichi ^c   Urase, Fumiaki ^d   Maeda, Yasuhiro ^d   Iwasaka, Toshiji ^c  

^a Kishiwada City Hospital   (Japan)

^b Saiseikai Izuo Hospital   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d KINKI UNIVERSITY   (Japan)

Author keywords

Adiponectin; Atherothrombosis; Hyperlipidemia; Monocyte chemoattractant protein 1; Pitavastatin

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ADIPONECTIN; CD40 LIGAND; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PITAVASTATIN; SIMVASTATIN; THROMBOPLASTIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTIOCYTE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; TREATMENT DURATION; UPREGULATION;

ADIPONECTIN; ADULT; AGED; ATHEROSCLEROSIS; CD40 LIGAND; CELL-DERIVED MICROPARTICLES; CHEMOKINE CCL2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; P-SELECTIN; QUINOLINES; T-LYMPHOCYTES; THROMBOPHILIA; THROMBOPLASTIN; U937 CELLS;

EID: 69549092436     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832e0618     Document Type: Article

References (57)

1. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
2. Croft KD, Beilin LJ, Vandongen R, Rouse I, Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia. Atherosclerosis 1990; 83:101-109. (Pubitemid 20237868)
3. Chobanian AV. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia co-exist. Hypertension 1991; 18:130-131.
4. Fogelman A, Schechter I, Seager J, Hokom M, Child JS, Edwards PA, et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in macrophages. Proc Natl Acad Sci U S A 1980; 77:2214-2218. (Pubitemid 10089629)
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
6. Nelken N, Coughlin S, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88:1121-1127.
7. Yla-Herttuala S, Lipton B, Rosenfeld M, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 1991; 80:5252-5256. (Pubitemid 21914722)
8. Reckless J, Rubin E, Verstuyft J, Metcalfe JC, Grainger DJ. Monocyte chemoattractant protein-1, but not tumor necrosis factor is correlated with monocyte infiltration in mouse lipid lesions. Circulation 1999; 99:2310-2316. (Pubitemid 29201139)
9. Wang GP, Deng ZD, Ni J, Qu ZL. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 1997; 133:31-36. (Pubitemid 27322114)
10. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101:2889-2895. (Pubitemid 30415877)
11. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039-2046.
12. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296-1301. (Pubitemid 30728130)
13. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83. (Pubitemid 29299050)
14. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patients. Artherioscler Thromb Vasc Biol 2000; 20:1595-1599. (Pubitemid 30353893)
15. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935. (Pubitemid 32472900)
16. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectin. Circulation 1999; 100:2473-2476. (Pubitemid 30005109)
17. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021-45026. (Pubitemid 37377262)
18. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46:1543-1549. (Pubitemid 37518575)
19. Scandinavian Simbvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
20. West of Scotland Coronary Prevention Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445.
21. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of ahterosclerosis. J Am Coll Cardiol 1998; 32:2057-2064. (Pubitemid 29010476)
22. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation 2001; 103:2531-2534. (Pubitemid 32521959)
23. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Plentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80:1095-1100. (Pubitemid 30483228)
24. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 163:157-164. (Pubitemid 34615738)
25. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-bind, three-group parallel comparison. Arzeimittelforschung 2002; 52:251-255. (Pubitemid 34438222)
26. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 2004; 109:790-796. (Pubitemid 38222901)
27. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM Jr, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 2004; 110:3472-3479. (Pubitemid 39602226)
28. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through apoB48 receptor-dependent mechanism. Artherioscler Thromb Vasc Biol 2005; 25:424-429. (Pubitemid 40189168)
29. Wang J, Tokoro T, Matsui K, Higa S, Kitajima J. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 2005; 76:2257-2268. (Pubitemid 40283650)
30. The Expert Committee on the Guideline for Diagnosis and Treatment of Hyperlipidemia. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemia, Japan Atherosclerosis Society (JAS): Guideline for diagnosis and treatment of hyperlipidemias in adults. Doumyakukouka 1997; 25:1-34.
31. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ECDCDM). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1):S5-S20.
32. Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, et al. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85:326-330. (Pubitemid 32140580)
33. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003; 89:506-512. (Pubitemid 36329242)
34. Bursill CA, Channon KM, Greaves DR. The role of chemokines in ahterosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004; 15:145-149.
35. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med 2004; 36:98-118.
36. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87:5134-5138. (Pubitemid 20224287)
37. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioacler Thromb Vasc Biol 2001; 21:327-334. (Pubitemid 32199112)
38. De Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman WM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107:690-695.
39. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, Buerke M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Cir J 2005; 69:1484-1489. (Pubitemid 41743963)
40. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on inflammatory markers study: a substudy of achieve cholesterol targets fast with atorvastatin stratified titration. Am Heart J 2007; 153:881-888. (Pubitemid 46360395)
41. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95:858-866.
42. 2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Artherioscler Thromb Vasc Biol 2005; 25:2005-2011.
43. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-1063. (Pubitemid 32200177)
44. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32:47-50. (Pubitemid 30143606)
45. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88:3236-3240. (Pubitemid 36877499)
46. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMGCoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010.
47. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-1332.
48. Fujino M, Miura S, Matsuo Y, Tanigawa H, Kawamura A, Saku K. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Atherosclerosis 2006; 187:301-308. (Pubitemid 43963026)
49. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2006; 414:813-820.
50. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drug Today 2004; 40:975-990.
51. Zeng L, Xu H, Chew TL, Chisholm R, Sadechi MM, Kanwar YS, et al. Simvastatin modulates angiotensin II signaling pathway by preventing Rac 1-mediated upregulation of p27. J Am Soc Nephrol 2004; 15:1711-1720. (Pubitemid 38822049)
52. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008; 57:380-386. (Pubitemid 351178728)
53. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Kim DS, et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis 2004; 177:147-153.
54. Leu HB, Wu CC, Wu TC, Lin SJ, Chen JW. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. J Formos Med Assoc 2004; 103:914-920.
55. Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb 2007; 36:1-8.
56. Nomura S, Shouzu A, Omoto S, Inami N, Tanaka A, Namba M, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res 2008; 122:39-45. (Pubitemid 351611655)
57. Erol A. The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins: statins activate the generation of metabolically more capable adipocytes. Med Hypotheses 2005; 64:69-73. (Pubitemid 39469237)